BPC-157

How BPC-157 is studied in tissue repair

Dosing evidence

Dose at a Glance

FDA-Approved Dose

None BPC-157 is not an FDA-approved drug.

Human SC Protocol

Not established No completed human SC dose-finding program has established a:

• starting dose

• optimal dose

• maximum dose

• escalation schedule

• maintenance dose

• dose-response relationship

• optimal frequency

• optimal treatment duration

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 3

FDA’s 2026 review found no human pharmacokinetic data after SC administration.

Current Community Protocol-Page Cluster

In the current protocol-page comparison used for this Navaro audit, the main community range clusters around approximately:

250-500 mcg/day SC with substantial variation.

Published community schedules also include:

• approximately 200 mcg/day

• 250 mcg/day

• 400-600 mcg/day

• 250 mcg twice daily

• 500 mcg twice daily in some higher protocols

• 4-8 week cycles

• longer 8-12 week cycles

Evidence classification Community protocol-page cluster not:

Clinically validated SC dosing EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 4

Agreement between community pages documents how the compound is being used.

It does not establish the optimal human dose.

Current Navaro 250 mcg BID Regimen

The previous Navaro page used:

250 mcg twice daily as a standard-looking protocol.

That should be reclassified as:

Community protocol example not:

Clinical standard and not:

Typical human research dose

High-Dose Community Injury Regimen

The previous Navaro page also included:

500 mcg-1.5 mg per administration given:

2-3 times daily This can reach approximately:

4.5 mg/day I did not identify controlled completed human SC evidence validating:

• 1.5 mg SC per dose

• three SC doses per day

• 4.5 mg/day

• an eight-week high-dose course

• superior injury healing at those amounts

Production decision Remove from the main protocol section.

If Navaro documents it at all, classify it only as:

High-dose community protocol sometimes circulated online, with particularly weak support

Frequency at a Glance

Timing

There is no human evidence identified establishing that BPC-157 must be administered:

• morning

• evening

• before exercise

• after exercise

• fasted

• with food

• away from food

Verdict Evidence-based time-of-day requirement: None established Fasting requirement: None established Workout timing requirement: None established

Human SC Half-Life

Not established FDA specifically found no human pharmacokinetic data after:

• SC

• oral

• nasal

• transdermal

administration.

Animal IV studies found very short elimination half-lives, approximately 5.3 minutes in dogs and 15.2 minutes in rats, but those are animal IV values and should not be converted into a human SC dosing interval.

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 6

Production rule Do not write:

“BPC-157 human half-life is X minutes/hours” unless a dedicated human PK study supports that figure.

Verdict Human SC pharmacokinetics remain inadequately characterized

Cycle Length

Human Clinical SC Cycle

None established

Critical SC Protocol Warning

The commonly repeated 250-500 mcg/day SC range remains community-derived.

The current randomized SC hamstring trial may materially improve the evidence base, but it has not yet produced completed efficacy data.

Therefore it cannot currently establish:

• effective dose

• optimal dose

• optimal frequency

• cycle duration

• results timeline

Critical Route Warning

Human exposure by one route cannot simply be transferred to another route.

For example:

2-4 mg intra-articular ≠ 2-4 mg SC 10-20 mg IV ≠ evidence for high-dose SC use 80 mg rectal enema ≠ evidence for oral or SC treatment intra-articular knee injection ≠ proof that nearby SC injection is superior

Critical Product-Identity Warning

BPC-157 free base and BPC-157 acetate are different bulk drug substances.

FDA specifically found inconsistent naming and incomplete characterization across nomination materials and public information.

A product labeled only:

BPC-157 may not tell the reader:

• exact API form

• impurity profile

• aggregation status

• endotoxin level

• microbial quality

• manufacturing quality

Protocol Logic Check

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 10

Question Verdict Is BPC-157 a 15-amino-acid peptide? Yes Does meaningful animal research exist? Yes Does direct human exposure exist? Yes Is “animal evidence only” still accurate? No Is completed human evidence still very limited? Yes Does a completed human SC dose-finding trial exist? No Is a randomized SC trial underway? Yes Does that trial have completed efficacy results? No Is 250 mcg/day clinically established? No Is 250-500 mcg/day common in community protocols?

Yes Is 250 mcg BID a clinical standard? No Is 500 mcg-1.5 mg 2-3× daily clinically validated? No Should that high-dose regimen remain in the main protocol?

No Is once-daily SC currently being studied? Yes Is once-daily SC proven optimal? No Is twice-daily SC proven superior? No Is local SC injection near injury proven superior? No Does the knee study validate nearby SC injection? No Is abdominal SC proven to create whole-body repair?

No Is human SC half-life established? No Does animal IV half-life establish human SC timing? No Is morning dosing required? No Is evening dosing required? No Is fasting required? No evidence Is a 4-8 week clinical cycle established? No Is week 8 a proven diminishing-returns threshold? No Is receptor-reset cycling established? No Is oral bioavailability established? No Is “Dopamine Buffer” a recognized human pharmacologic property?

No Is anhedonia an established characteristic adverse effect?

No Is active malignancy a formal FDA-labeled contraindication?

No Is angiogenesis a reasonable theoretical malignancy caution?

Yes Is BPC-157 + TB-500 synergy clinically established? No Is same-vial compatibility established? No Is BPC-157 FDA approved? No Did FDA staff recommend 503A inclusion in May 2026?

No Did PCAC later recommend inclusion? Yes Is the PCAC recommendation final FDA action? No Is BPC-157 WADA prohibited? Yes

Abdominal / Remote SC Administration

Remote abdominal SC administration is also common in community protocols.

There is no completed human SC PK or efficacy study demonstrating that a specific abdominal microgram dose creates a predictable:

• systemic anti-inflammatory response

• whole-body repair effect

• generalized tissue-regeneration effect

Correct wording Remote SC administration is common in community use, but human systemic exposure and clinical whole-body effects remain inadequately characterized.

Oral BPC-157

Oral BPC-157 is frequently marketed for gastrointestinal goals.

An often-repeated argument is that resistance to gastric degradation proves oral activity.

That conclusion is too strong.

FDA found:

no human oral pharmacokinetic data and no posted results from the historical oral Phase 1 registration.

Important distinction Experimental stability does not automatically establish:

• oral absorption

• systemic bioavailability

• oral clinical efficacy

• equivalence to SC administration

Verdict Human oral therapeutic dose and bioavailability remain unestablished

Remove From Main Protocol

500 mcg-1.5 mg 2-3× daily If documented at all:

High-dose community protocol, particularly weak support

Remove

Diminishing returns after week 8

Change

Morning / Evening to:

No evidence-based timing requirement established

Remove

Dopamine Buffer

Protocol logic check

No established clinical SC dosing standard.

Medical literature and study context

BPC-157

Stable Gastric Pentadecapeptide • Tissue-Repair Research • Gastrointestinal Biology •

Experimental Musculoskeletal Use

At a Glance

What is BPC-157?

BPC-157 is a synthetic peptide composed of 15 amino acids .

The sequence associated with BPC-157 free base is:

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val or:

GEPPPGKPADDAGLV It has also appeared in research as:

PL 14736 and:

Bepecin FDA describes BPC-157 as a reported pentadecapeptide associated with gastric BPC research. FDA also makes an important product-identity distinction between BPC-157 free base and BPC-157 acetate, which are different active pharmaceutical ingredients and different bulk drug substances.

Research has focused on:

• gastrointestinal protection and repair

• tendon injury

• ligament and connective-tissue biology

• skeletal muscle injury

• wound healing

• angiogenesis

• vascular signaling

• nitric-oxide biology

• fibroblast activity

• nerve injury

• inflammatory signaling

The experimental literature is broad.

The human clinical evidence remains small.

How Well Studied Is BPC-157?

Evidence area Assessment Mechanistic / cell research Meaningful Animal gastrointestinal research Extensive Animal tendon / muscle research Meaningful Animal vascular / wound research Meaningful Animal nerve research Meaningful Direct human exposure Exists but limited Controlled human efficacy evidence Very limited Completed human SC efficacy evidence Not established Human SC dose-finding Not established Human SC pharmacokinetics Not established Long-term human systemic safety Not established Current randomized SC research Yes, underway FDA-approved drug No FDA’s 2026 evaluation identified five completed human studies involving BPC-157, but they used several different routes and were generally small, short and exploratory. FDA concluded that there is insufficient clinical safety information to characterize the human safety profile.

Overall Evidence Strength Very limited human clinical evidence with substantial preclinical research That is more accurate than:

“animal evidence only” but also much more cautious than:

“clinically proven healing peptide.”

What May It Help With?

Human evidence currently suggests possible signals for:

Knee Pain A small retrospective intra-articular study reported pain improvement in many participants.

This is:

very weak observational human evidence not:

proof that BPC-157 regenerates cartilage, tendon or ligament tissue.

Interstitial Cystitis A small uncontrolled pilot involving direct bladder-wall administration reported symptom improvement.

This is:

very small route-specific human evidence not:

evidence for systemic SC treatment.

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 2

Ulcerative Colitis A randomized placebo-controlled rectal-enema study exists, but the available report is limited and FDA concluded that the evidence was inadequate to establish efficacy or safety for ulcerative colitis.

Musculoskeletal Repair Human SC efficacy has not yet been established .

A randomized Phase 2 study is now testing SC BPC-157 in MRI-confirmed grade II hamstring strain, but results are not yet available.

What Is Not Established?

Completed human SC research has not established that BPC-157 reliably:

• heals tendon tears

• heals ligament tears

• regenerates cartilage

• heals meniscal injury

• accelerates skeletal-muscle repair

• shortens return-to-sport time

• improves MRI-confirmed structural healing

• treats Crohn’s disease

• treats ulcerative colitis through systemic injection

• repairs peripheral nerves in humans

• treats neuropathy

• reduces whole-body inflammation

• prevents surgery

• replaces rehabilitation

• replaces appropriate imaging

• replaces diagnosis of serious musculoskeletal injury

The ongoing hamstring trial itself combines investigational BPC-157 with standardized rehabilitation , rather than treating the peptide as a substitute for rehabilitation.

Current SC Clinical Research

A randomized Phase 2 hamstring trial is studying:

SC BPC-157 once daily for 14 days alongside standardized rehabilitation.

The study is:

• randomized

• double-blind

• placebo-controlled

• Phase 2

• focused on acute MRI-confirmed grade II hamstring strain

Key outcomes include:

• time to unrestricted return to sport

• change in MRI-assessed injury volume

Assessments occur at several points through day 56, with later recurrence follow-up.

Current status Study underway Results No completed efficacy results available Therefore:

Once-daily administration is being studied. It is not yet proven optimal.

Completed Human SC Evidence

No optimal frequency established There is no completed human SC trial proving superiority of:

• once daily

• twice daily

• three times daily

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 5

• several times weekly

• intermittent use

Ongoing Human SC Research

Once daily for 14 days is currently being tested in the Phase 2 hamstring trial.

Verdict Once daily: Currently under formal study Once daily proven optimal: No Twice daily proven superior: No Three times daily proven superior: No

Current SC Research

14 days is being studied in the ongoing hamstring Phase 2 trial.

That does not establish 14 days as the optimal treatment cycle.

Community

Common protocol cycles include:

• 4 weeks

• 4-6 weeks

• 4-8 weeks

• 8-12 weeks

Evidence classification Community convention No human evidence establishes a mandatory stop point at:

• week 4

• week 6

• week 8

• week 12

Receptor Reset

No evidence There is no established single clinical BPC-157 receptor with a documented desensitization-reset schedule.

There is no evidence that:

• a washout restores sensitivity

• weeks off are required

• receptor reset occurs after a defined period

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 7

Verdict No established receptor-reset requirement

“Diminishing Returns After Week 8”

The previous Navaro protocol stated that treatment beyond week eight may experience diminishing returns.

I found no controlled human evidence identifying:

week eight as a biological threshold for reduced BPC-157 response.

Verdict Remove

Expected Results Timeline

Human Clinical / Research Timeline

Days 1-14 The active hamstring study is evaluating participants during this period, but there are currently no efficacy results establishing expected improvement.

Days 28-56 The same trial includes later assessment of recovery and injury outcomes, but again, results are not yet available.

Long Term Human long-term efficacy and safety remain inadequately characterized.

Clinical conclusion There is currently no validated human SC BPC-157 results timeline for:

• pain relief

• tendon healing

• ligament healing

• muscle healing

• collagen repair

• return to sport

• gastrointestinal healing

Community / Anecdotal Timeline

Community users commonly describe:

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 8

First several days Possible subjective changes in:

• pain

• inflammation

• stiffness

Approximately 2-4 weeks Community reports often describe more noticeable recovery or pain changes.

Approximately 4-8 weeks This is a common community cycle and review window.

Approximately 8-12 weeks Some protocols continue this long, especially for chronic injuries.

Classification Community-reported / anecdotal These timelines should not be displayed as predictable controlled-human outcomes.

Critical Human-Evidence Warning

BPC-157 should no longer be described as having no human exposure data.

Several small human studies exist.

However , they used:

• rectal

• intra-articular

• intravesical

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 9

• intravenous

routes.

These studies do not create a unified human dosing program.

They do not validate the popular SC protocol.

Human Research in Detail

1. Healthy-Volunteer Rectal Research

FDA identified Phase 1 meeting abstracts involving healthy subjects receiving BPC-157 by rectal enema.

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 11

Across the studies, up to:

2 mg/kg was administered.

FDA summarizes:

24 healthy subjects receiving BPC-157 with repeated administration lasting up to:

8 days.

The most frequently reported adverse events were:

• headache

• flatulence

with no obvious difference in frequency or severity compared with placebo in the available abstracts.

What this establishes Human exposure occurred and limited short-term rectal tolerability information exists.

What it does not establish

• SC safety

• SC efficacy

• chronic safety

• tendon healing

• ligament healing

• oral bioavailability

• 250-500 mcg SC dosing

2. Human Ulcerative-Colitis Study

FDA identified a multicenter:

randomized double-blind placebo-controlled study involving:

53 subjects with mild-to-moderate ulcerative colitis.

Participants were randomized approximately 1:1 to:

BPC-157 enema 80 mg once daily or placebo for:

2 weeks.

The study reported a greater mean change in Disease Activity Index in the BPC-157 group.

However , FDA highlighted major limitations involving:

• incomplete endpoint reporting

• unclear inclusion criteria

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 12

• limited statistical information

• exploratory design

• insufficient safety detail

FDA concluded that the available evidence was inadequate to support efficacy and safety for ulcerative colitis.

Correct classification Very limited controlled human evidence, inconclusive not:

BPC-157 proven effective for ulcerative colitis

3. Intra-Articular Knee Study

A small retrospective study included:

17 patients with knee pain.

Participants received approximately:

2-4 mg intra-articularly in:

1-2 injections.

Some participants also received thymosin beta-4.

Pain relief was reported by many participants.

Major limitations

• retrospective design

• tiny sample

• no randomized control

• no blinding

• multiple knee diagnoses

• subjective follow-up

• limited structural imaging

• some participants received another peptide

• pain improvement does not establish tissue regeneration

Correct classification Very weak observational human evidence for knee-pain improvement after intra-articular administration not:

proof of tissue healing and not:

proof of nearby SC superiority EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 13

4. Interstitial-Cystitis Pilot

A 2024 pilot involved:

12 women with moderate-to-severe interstitial cystitis.

Investigators administered:

1 mg BPC-157 at 10 bladder-wall sites for:

10 mg total during one procedure.

The study reported symptom improvement and no adverse events in the small cohort.

Limitations

• N=12

• no placebo

• no blinding

• single clinic

• unusual route

• subjective outcomes

• cannot be generalized to SC treatment

Correct classification Very small uncontrolled route-specific human signal

5. Intravenous Human Pilot

A 2025 study administered BPC-157 intravenously to:

2 healthy adults The exposures were:

Day 1: 10 mg IV Day 2: 20 mg IV with each infusion given over approximately one hour .

No adverse effects were reported in those two participants during the monitored period.

Critical limitation N = 2 This provides only:

extremely preliminary short-term IV tolerability information It does not establish:

• chronic safety

• long-term toxicity

• cancer safety

• reproductive safety

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 14

• SC safety

• injury-healing efficacy

• dose-response efficacy

6. Historical Oral Phase 1 Registration

FDA identified an older Phase 1 oral study registration.

The planned design included:

Single-dose phase

• 1 mg

• 3 mg

• 6 mg

oral BPC-157 Repeated phase 3 mg orally every 8 hours for two weeks Estimated enrollment:

42 participants FDA found:

no posted results and:

no associated published completed study.

Production rule A registered planned dose is not a validated therapeutic dose.

7. Current Phase 2 Hamstring Study

The most important current human research update is:

NCT07437547 A randomized, double-blind, placebo-controlled Phase 2 trial of BPC-157 for acute MRI-confirmed grade II hamstring strain.

Estimated enrollment:

120 adults Participants are randomized to:

• BPC-157

• placebo

Both groups receive:

standardized rehabilitation The investigational treatment is given:

subcutaneously once daily for 14 days EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 15

Key outcomes include:

• time to unrestricted return to sport

• MRI-assessed change in injury volume

Current status The registry lists the study as active and ongoing.

Primary completion Estimated in 2027.

Current efficacy results None Why this matters This is much closer to the type of human evidence needed to answer the actual community questions about:

• SC route

• sports injury

• functional recovery

• MRI-confirmed structural change

What Navaro must not do Do not pre-write the result.

Until the trial reports outcomes:

SC effectiveness remains unestablished.

Human Evidence Summary

Human evidence area Evidence quality Rectal short-term tolerability Limited Ulcerative colitis Very limited / inconclusive Knee pain Very weak observational Interstitial cystitis Very small uncontrolled pilot IV short-term tolerability Extremely limited, N=2 Oral efficacy Not established Completed SC efficacy Not established Current SC hamstring trial Ongoing, no completed results Final human-evidence verdict Human exposure exists.

Human clinical validation remains very limited.

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 16

What the Animal Research Actually Shows

The largest part of the BPC-157 literature remains:

animal and laboratory research That research is important for biological plausibility.

It should not be rewritten as human clinical proof.

Tendon Research

Experimental tendon research has reported effects involving:

• tendon-fibroblast outgrowth

• cell survival

• fibroblast migration

• FAK signaling

• paxillin signaling

A tendon-fibroblast study found increased ex-vivo fibroblast outgrowth and in-vitro migration under experimental conditions.

What this supports Mechanistic plausibility for tendon-repair research What it does not support 250 mcg SC heals a human tendon tear

Muscle Research

Animal studies have reported improved healing in experimentally injured skeletal muscle.

Evidence classification Animal not:

Human muscle-recovery evidence

Nerve Research

BPC-157 has been investigated in animal nerve-injury models.

Experimental findings have included functional and histologic changes after nerve injury.

Evidence classification Preclinical not:

Validated human neuropathy treatment EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 17

Gastrointestinal Research

A large portion of BPC-157 research involves animal gastrointestinal models, including:

• ulcers

• intestinal injury

• fistulas

• hepatic injury

• vascular obstruction

• anastomotic healing

FDA acknowledges broad preclinical findings but notes that dose-response relationships have not been established, molecular targets remain unidentified, and mechanisms remain poorly understood.

Critical distinction Extensive animal GI evidence does not equal:

proven treatment of human IBD

Mechanism

There is no single clinically established receptor that explains BPC-157.

FDA specifically notes that:

• molecular targets have not been adequately identified

• dose-response relationships remain unclear

• mechanisms remain poorly understood

Several experimental pathways repeatedly appear in the literature.

VEGFR2 / Angiogenesis

Experimental research suggests that BPC-157 can influence angiogenic signaling involving:

VEGFR2 and downstream vascular pathways.

Simple version BPC-157 appears capable of influencing signals involved in formation and remodeling of blood vessels in experimental systems.

Evidence classification Mechanistic / preclinical not:

Proven systemic human angiogenic therapy EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 18

Nitric Oxide / Vascular Signaling

Animal and laboratory research has linked BPC-157 with:

• endothelial nitric-oxide signaling

• vascular tone

• blood-vessel biology

• angiogenesis

FDA lists stimulation of nitric-oxide synthesis among the hypothesized mechanisms reported in preclinical work.

Production correction Do not simplify this to:

“BPC-157 increases nitric oxide, therefore it causes dizziness.”

Human clinical significance remains uncertain.

FAK / Paxillin

Tendon-fibroblast research has implicated:

FAK and:

paxillin signaling in BPC-157-associated cell migration.

Evidence classification Cellular mechanism not:

Clinical proof of injury healing

Inflammation

Preclinical research repeatedly reports modulation of inflammatory signaling.

The human evidence is not developed enough to classify BPC-157 as a clinically established:

anti-inflammatory drug

“Dopamine Buffer”

Remove The previous Navaro page used:

Dopamine Buffer

as a compound property.

Preclinical CNS research involving dopamine does not establish a recognized human pharmacological property called:

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 19

dopamine buffering and does not establish that BPC-157 “balances dopamine.”

Verdict Remove from Compound Profile

Anhedonia

Community reports sometimes mention:

anhedonia

The available human safety studies do not establish anhedonia as a characteristic BPC-157 adverse effect.

Correct classification If included:

Community-reported / causality uncertain Do not attach a confident dopamine mechanism to it.

Local SC Injection Near the Injury

This is one of the most important protocol corrections.

Community protocols often recommend administering SC BPC-157 close to:

• tendon

• knee

• joint

• muscle injury

What human evidence exists?

The published knee study used:

intra-articular administration directly into the knee joint.

That is not the same route as:

SC injection into nearby skin.

The active hamstring study uses SC administration, but does not yet provide completed evidence that proximity to the injury improves efficacy.

No controlled human evidence currently establishes that:

• local SC is superior to remote SC

• distance from the injury predicts efficacy

• an SC injection near a tendon reaches that tendon better

• nearby SC administration improves structural healing

• abdominal SC is inferior

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 20

Verdict Local SC administration: Community practice Local superiority: Not established

FDA / Regulatory Status

FDA-Approved Drug

No Neither BPC-157 free base nor BPC-157 acetate is an FDA-approved drug component. FDA’s review also states that BPC-157 was not identified as a component of an approved product in another country in the materials reviewed.

FDA 2026 Scientific Evaluation

FDA’s detailed evaluation is dated:

May 11, 2026 FDA evaluated:

• BPC-157 free base

• BPC-157 acetate

for possible inclusion on the Section 503A Bulks List.

FDA evaluated ulcerative colitis as the principal proposed use in its detailed clinical analysis.

FDA staff concluded that the available criteria weighed:

against inclusion because of concerns involving:

• inadequate physicochemical characterization

• impurities

• aggregation

• immunogenicity

• limited safety information

• insufficient efficacy evidence

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 30

FDA proposed:

not adding BPC-157 free base or BPC-157 acetate to the 503A Bulks List.

Nomination Nuance

The original BPC-157 nominations had been withdrawn.

FDA nevertheless elected to continue evaluating BPC-157 free base and acetate on its own initiative and presented them to PCAC.

That is important because the regulatory history is more complicated than simply:

“A nomination is currently pending.”

July 23, 2026 PCAC Recommendation

The external Pharmacy Compounding Advisory Committee subsequently recommended inclusion.

The reported vote tally used in this Navaro reconciliation was:

8 in favor 6 against 1 abstention The recommendation went against FDA staff’s scientific proposal.

Critical distinction PCAC provides:

independent advisory input The FDA’s own meeting page states that advisory committee recommendations are non-binding.

Therefore the vote does not itself mean:

• FDA drug approval

• final inclusion on the 503A Bulks List

• proven safety

• proven efficacy

• an FDA prescribing dose

• an approved clinical protocol

Final FDA Action

Status as of August 18, 2026

No final FDA determination adding BPC-157 free base or acetate to the final 503A Bulks List was located in this last review.

FDA’s current 503A information still describes the agency as developing and modifying the list through its regulatory process and distinguishes advisory input from final agency action.

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 31

Final Navaro wording FDA-approved drug: No FDA staff 503A evaluation: Unfavorable July 23, 2026 PCAC recommendation: Favorable, reported 8-6 with one abstention Final FDA action: No final determination located as of August 18, 2026; separate from the advisory recommendation Critical regulatory warning Do not write “FDA approved BPC-157 for compounding.”

That would overstate what occurred.

Important Research Note

BPC-157 information online frequently mixes several evidence categories.

They should remain separate.

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 32

1. Human Rectal BPC-157

Direct exposure exists.

This gives limited short-term human information.

It does not establish SC dosing.

2. Human Intra-Articular BPC-157

Very small knee evidence exists.

It does not establish nearby SC administration.

3. Human Intravesical BPC-157

Very small bladder evidence exists.

It is highly route-specific.

4. Human IV BPC-157

Two-person short-term exposure exists.

It is far too small to establish general safety.

5. Human SC BPC-157

A meaningful randomized Phase 2 study is underway.

No completed results yet.

6. Animal / Laboratory BPC-157

This remains the largest efficacy evidence category.

It provides:

biological plausibility not:

a validated human dose

7. Community SC BPC-157

This is where the familiar:

• 250 mcg

• 500 mcg

• once daily

• twice daily

• local injection

• 4-8 week cycles

primarily originate.

These belong under:

Community protocols EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 33

Research at a Glance

FDA-Approved-Label Human Evidence

None

Direct Human Exposure

Exists but remains very limited Completed routes include:

• rectal

• intra-articular

• intravesical

• IV

An SC Phase 2 trial is underway.

Controlled Human Efficacy Evidence

Very limited and inconclusive

Human Musculoskeletal Evidence

Very weak completed evidence The most meaningful randomized human SC sports-injury trial is still underway.

Animal / Cell Evidence

Substantial Especially for:

• tendon biology

• muscle injury

• GI injury

• vascular signaling

• nerve injury

• wound-related pathways

Community / Anecdotal Evidence

Extensive Useful for documenting how BPC-157 is actually used outside controlled research.

Not sufficient to establish:

• optimal SC dose

• optimal frequency

• best injection location

• cycle length

• human results timeline

• maximum safe dose

• long-term safety

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 34

Evidence Strength

Overall Evidence Rating

Very limited human clinical evidence with substantial preclinical research Stronger Evidence For

• broad experimental tissue-repair biology

• animal tendon-repair effects

• animal muscle-repair effects

• animal gastrointestinal protection

• experimental angiogenic signaling

• fibroblast migration

• vascular and nitric-oxide pathway effects

Limited Human Evidence For

• short-term rectal exposure

• intra-articular knee-pain improvement

• intravesical interstitial-cystitis symptom improvement

• extremely limited short-term IV tolerability

Weak / Unestablished Evidence For

• SC injury healing

• human tendon healing

• human ligament healing

• human muscle repair

• systemic GI treatment

• oral efficacy

• local SC superiority

• 250 mcg versus 500 mcg superiority

• twice-daily superiority

• high-dose injury regimens

• 4-8 week cycle optimization

• receptor reset

• human SC half-life

• long-term injectable safety

Current Navaro Page Corrections

Replace

Typical dose: 250 mcg twice daily with:

Human SC protocol: Not established and separately:

Current community protocol-page cluster: approximately 250-500 mcg/day SC, with substantial variation EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 35

Replace

Standard Protocol with:

Community Protocol Examples

Reclassify

250 mcg BID ×6 weeks as:

Community protocol example not:

Clinical standard

Reclassify

Local SC injection near injury as:

Community practice; superiority not established

Final Bottom Line

BPC-157 is one of the clearest examples of how a compound can have a large experimental literature while still having a very small clinically useful human evidence base .

The older statement:

“BPC-157 only has animal evidence” is no longer accurate.

Human exposure has now been documented through several routes.

Healthy volunteers received rectal BPC-157.

A randomized ulcerative-colitis study used an 80 mg rectal enema.

A small knee series used 2-4 mg intra-articularly.

A small interstitial-cystitis pilot used 10 mg directly in the bladder wall.

Two healthy adults received 10 mg and 20 mg intravenously.

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 38

And a randomized Phase 2 study is now testing SC BPC-157 once daily for 14 days in MRI-confirmed hamstring injury.

That is substantially more human exposure than older BPC-157 summaries acknowledged.

But the opposite mistake would be equally serious.

Those studies do not establish that:

250 mcg SC is the correct dose or:

500 mcg SC is the correct dose or:

250 mcg twice daily is the standard protocol or:

BPC-157 should be injected next to an injury or:

4-8 weeks is the correct treatment cycle.

The current community protocol-page cluster remains approximately:

250-500 mcg/day SC with substantial variation.

That information belongs on Navaro because it accurately documents real-world community use.

It should remain:

Community protocol not:

Human clinical dose The previous Navaro 250 mcg twice-daily regimen can therefore remain as a community example, but it should not be displayed as the clinical evidence anchor .

The previous high-dose injury regimen of:

500 mcg-1.5 mg two or three times daily has even weaker support and should be removed from the main protocol section.

The injection-location claim also needs strict evidence labeling.

The completed human musculoskeletal study involved:

intra-articular knee administration not:

SC injection into skin near an injury Therefore:

“inject as close to the injury as possible” remains community practice rather than demonstrated human pharmacology.

The current hamstring trial may eventually provide meaningful SC evidence, but the correct conclusion today is:

results pending.

Safety requires the same discipline.

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 39

The very small completed human studies did not reveal a clear major safety signal, but they are too small and too short to establish systemic safety.

FDA continues to identify:

• limited human safety information

• incomplete API characterization

• aggregation concerns

• peptide-related impurities

• potential immunogenicity

particularly for injectable use.

FDA also identified three spontaneous injectable adverse-event reports involving:

• injection-site reaction

• shortness of breath

• pigmentation changes

while emphasizing that causality cannot be established from those reports alone.

Meanwhile, repeat-dose animal toxicology produced signals involving:

• clotting measurements

• ALT

• glucose

• triglycerides

and adequate carcinogenicity data remain unavailable.

The cancer section therefore needs balance.

BPC-157 has genuine experimental angiogenic activity.

That gives a rational basis for extra caution in active malignancy.

It does not establish that BPC-157 causes human cancer .

And because there is no approved BPC-157 drug label, active malignancy should not be presented as an FDA-labeled absolute contraindication.

The correct classification is:

unresolved mechanism-based precaution Several other claims from the older live page should be removed.

Dopamine Buffer is not an established human pharmacological property.

Anhedonia from dopamine buffering is not an established characteristic adverse effect.

Corticosteroids reduce BPC-157 effectiveness has not been established as a human interaction.

MCAS and histamine intolerance are not validated BPC-157-specific contraindications.

The regulatory story also requires careful wording.

FDA staff’s May 2026 scientific evaluation concluded that the evidence weighed against putting BPC-157 free base and acetate on the 503A Bulks List.

The external PCAC subsequently recommended inclusion.

Those are different steps.

FDA’s own advisory-committee page explicitly says committee recommendations are non-binding.

As of the final August 18, 2026 review for this production master , I did not locate a final FDA action adding BPC-157 to the final Bulks List.

Therefore Navaro should distinguish:

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 40

FDA-approved drug: No FDA staff scientific recommendation: Unfavorable PCAC advisory recommendation: Favorable Final FDA determination: Not located as completed as of August 18, 2026 Finally, the evidence hierarchy should remain visible throughout the page:

Completed human route-specific BPC-157 research separate from:

Ongoing human SC research separate from:

Animal BPC-157 research separate from:

Cellular / mechanistic BPC-157 research separate from:

Community SC protocols separate from:

Premixed BPC-157 combinations That prevents promising experimental biology from being converted into a clinical protocol simply because the same dose has been repeated across peptide websites.

The most accurate Navaro conclusion today is:

BPC-157 has substantial preclinical repair biology and more direct human exposure than older summaries acknowledged. However , the familiar systemic SC protocol remains clinically unvalidated. The ongoing randomized hamstring trial is the study most likely to materially change that assessment, but until completed results exist, Navaro should not pre-write its outcome.

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 41

Independent evidence

Very limited human clinical evidence

Controlled human SC efficacy, dose-finding, pharmacokinetics, and long-term systemic safety remain unestablished.

Storage

Formulation / Stability

There is no FDA-approved injectable BPC-157 product providing one universally validated:

• vial strength

• diluent

• reconstitution volume

• final concentration

• pH

• refrigerated stability period

• room-temperature stability period

• 14-day rule

• 28-day rule

• multidose beyond-use date

FDA notes that BPC-157 can be sensitive to:

• formulation

• processing

• environmental conditions

• aggregation

• degradation

Production rule Do not use a universal 28-day post-reconstitution rule unless the exact finished formulation has validated stability data.

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 29

Bulk-Peptide Storage Is Not Finished-Vial Stability

FDA’s review cites manufacturer information recommending very cold storage for dry bulk BPC-157 material.

That does not establish:

how long a reconstituted multidose vial remains stable after:

• water is added

• a specific concentration is prepared

• preservatives are introduced

• a rubber stopper is repeatedly punctured

• refrigeration conditions vary

Correct distinction Bulk API storage is not:

validated reconstituted-product stability

Contraindications & cautions

Key Safety and Approval Facts

FDA-approved: No Human SC dose established: No Human SC half-life established: No Long-term systemic safety established: No Maximum safe SC dose established: No Cancer safety established: No Pregnancy safety established: No Pediatric safety established: No WADA: Prohibited at all times.

FDA continues to state that compounded BPC-157 may present immunogenicity concerns for certain routes and that peptide-related impurities and API characterization remain concerns. FDA says it has only limited safety-related information for the proposed routes.

Safety at a Glance

Human Safety Database

Small and inadequate FDA found no serious adverse events reported in the five small human studies it identified, but emphasized that:

• study sizes were small

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 21

• exposure duration was short

• doses were exploratory

• safety reporting was limited

• monitoring was unclear in several studies

Correct conclusion No major signal emerged in those very small studies.

That is not the same as:

“BPC-157 is proven safe.”

FDA Spontaneous Safety Reports

FDA searched FAERS through December 4, 2025 and identified three injectable BPC-157-associated reports.

Injection-Site Reaction

A woman reported:

• redness

• swelling

around injection sites.

She was also using injectable thymosin, which limits attribution.

Shortness of Breath

A man using compounded SC BPC-157 acetate for injury/inflammation reported shortness of breath requiring emergency-room evaluation.

Important details were missing.

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 22

Pigmentation Changes

A woman using a combined:

BPC-157 + TB-500 SC product developed:

• diffuse hyperpigmentation

• gingival darkening

The reaction reportedly recurred after rechallenge.

Because both peptides were present, the responsible ingredient could not be determined.

Important limitation FDA explicitly cautions that FAERS reports:

• do not prove causality

• may lack important details

• may contain confounding factors

• do not capture every adverse event

Production classification Post-market safety reports / causality uncertain not:

Established common adverse effects

Formal Contraindications

FDA-Labeled Contraindications

None There is no FDA-approved BPC-157 prescribing label.

Therefore Navaro should not present a list of cautions as though they were official drug-label contraindications.

Important Cautions

Active Malignancy / Recent Cancer Treatment

Experimental angiogenesis and tissue-remodeling effects create a theoretical concern.

Human cancer risk is unknown.

Classification Mechanism-based precaution not:

FDA-labeled absolute contraindication

Pregnancy / Breastfeeding

Adequate human pregnancy and breastfeeding safety data are unavailable.

FDA also identified major gaps in reproductive and developmental toxicology.

Classification Safety unknown

Children / Adolescents

There is no established pediatric dosing or safety program.

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 25

Classification Safety and dose not established

Anticoagulants / Bleeding or Clotting Disorders

No controlled human interaction study has established a BPC-157 anticoagulant interaction.

However , animal repeat-dose studies produced coagulation-related signals.

Correct wording Human interaction is unknown. Animal clotting-related findings justify caution, particularly in people with significant bleeding/clotting disorders or therapeutic anticoagulation, but this is not a proven clinical interaction.

Corticosteroids

The previous Navaro page stated that corticosteroids decrease BPC-157 effectiveness.

That should be removed.

Animal injury studies involving corticosteroid-related impairment do not establish a general human interaction in which corticosteroids block BPC-157.

Verdict Clinically established corticosteroid interaction: No

MCAS / Histamine Intolerance

No controlled human evidence identified establishes:

• MCAS as a specific BPC-157 contraindication

• predictable histamine release

• predictable histamine suppression

• a validated MCAS interaction

Verdict Remove as a specific formal BPC-157 caution unless direct human evidence is added

Autoimmune Disease

There is no validated clinical dataset showing predictable:

• immune activation

• immune suppression

• disease flare

• therapeutic benefit

in autoimmune disease.

Classification Human interaction unknown EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 26

BPC-157 Should Not Replace Injury Diagnosis

Because BPC-157 is widely described as a “healing peptide,” a practical risk is using subjective pain improvement as proof that a structural injury has healed.

It should not replace:

• MRI when clinically appropriate

• X-ray when clinically appropriate

• diagnosis of tendon rupture

• diagnosis of fracture

• diagnosis of infection

• surgical evaluation

• rehabilitation

• load management

The current Phase 2 trial itself uses MRI-confirmed injury and standardized rehabilitation.

Commonly Paired With

Use:

Commonly Paired With

rather than:

Synergistic Compounds unless controlled combination evidence exists.

TB-500 / Thymosin-Related Peptides

This is one of the most common BPC-157 community pairings.

The combination is frequently called:

Wolverine Human evidence The small knee study included some patients who received BPC-157 together with thymosin beta-4.

That does not establish:

• synergy

• an optimal ratio

• SC Wolverine dosing

• superior efficacy

• same-vial stability

• TB-500 fragment equivalence to full-length thymosin β4

Classification Community combination with extremely weak indirect human context

GHK-Cu

Frequently combined in community repair protocols and premixed blends.

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 27

Classification Community combination No controlled human study establishes superior efficacy for:

BPC-157 + GHK-Cu KPV Frequently paired for gut or inflammatory goals.

Classification Community combination No validated human BPC-157 + KPV combination protocol.

ARA-290 / Cibinetide

Sometimes paired for nerve or recovery goals.

Classification Community combination The compounds have distinct evidence bases.

Concurrent use does not establish synergy.

NAD+, Glutathione and Other Recovery Compounds

These often appear in broader community recovery protocols.

Production rule Concurrent popularity does not equal pharmacologic synergy

Ingredient Overlap / Redundancy

BPC-157 may already be included in products marketed as:

• Wolverine

• GLOW

• KLOW

• Tri-Heal

• other vendor-defined repair blends

Adding standalone BPC-157 to a blend that already contains it can create:

• duplicate exposure

• harder dose accounting

• harder adverse-effect attribution

• greater formulation complexity

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 28

This is primarily:

an ingredient-overlap problem not:

a formal contraindication

Current FDA Safety Position

FDA continues to list BPC-157 among bulk substances for which compounding may present significant safety risks.

FDA highlights:

• possible immunogenicity

• peptide-related impurities

• API characterization issues

• limited human safety information

The July FDA presentation also reiterated insufficient clinical safety information and significant characterization gaps.

WADA Status

BPC-157 is included under:

S0 Non-Approved Substances on the 2026 WADA Prohibited List.

Status Prohibited at all times Production wording Competitive sport: BPC-157 is WADA-prohibited.

Rewrite Safety

Separate:

1. limited human-study observations 2. FDA spontaneous safety reports 3. community-reported effects 4. animal toxicology signals 5. theoretical / mechanistic concerns EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 36

Rewrite Contraindications

Do not present active cancer as an official FDA contraindication.

Use:

Mechanism-based theoretical caution Remove unsupported BPC-specific claims involving:

• MCAS

• histamine intolerance

• autoimmune disease

• corticosteroid antagonism

unless direct human evidence is added.

Final Top Card

BPC-157

Stable Gastric Pentadecapeptide Evidence: Very limited human clinical evidence with substantial preclinical research What it is: Synthetic 15-amino-acid peptide associated with gastric BPC research Important identity issue: BPC-157 free base and BPC-157 acetate are different bulk drug substances Strongest efficacy evidence: Animal and laboratory tissue-repair research Direct human exposure: Yes, through several small route-specific studies Completed human SC efficacy evidence: None established Current SC clinical research: Randomized Phase 2 hamstring trial underway; once-daily SC administration for 14 days is being studied, with no completed efficacy results yet Human SC protocol: Not established Clinically validated SC dose: None Current community protocol-page cluster: Approximately 250-500 mcg/day SC, with lower , higher and twice-daily protocols also circulating Current Navaro 250 mcg BID regimen: Community protocol example, not a clinical standard High-dose 500 mcg-1.5 mg 2-3× daily regimen: Remove from main protocol; particularly weak support Optimal frequency: Unknown Once daily: Currently being formally studied, not yet proven optimal Twice-daily superiority: Not established Local SC injection superiority: Not established Human SC half-life: Not established Timing requirement: None established Fasting requirement: None established Clinical cycle: None established Receptor reset: No evidence Diminishing returns after week 8: Not established EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 37

Dopamine Buffer: Remove Long-term systemic safety: Unknown FDA-approved drug: No FDA staff 503A evaluation: Unfavorable July 23, 2026 PCAC recommendation: Favorable, reported 8-6 with one abstention Final FDA action: No final FDA determination located as of August 18, 2026; separate from the nonbinding advisory recommendation WADA: Prohibited at all times Critical Human-Evidence Warning BPC-157 is no longer accurately described as having no human exposure data. Several small human studies exist. However , they involve different routes, populations and exploratory doses, and none validates the popular systemic SC dosing protocols.

Critical SC Protocol Warning The commonly repeated 250-500 mcg/day SC protocol remains community-derived. The current Phase 2 SC hamstring trial is important, but no completed efficacy results have yet been reported, so it cannot currently establish an effective dose, optimal frequency or predictable results timeline.

Critical Route Warning Intra-articular , rectal, intravesical and IV human studies cannot be converted directly into an SC protocol. The knee study also does not prove that injecting subcutaneously near an injury is superior to remote SC administration.

Critical Product-Identity Warning “BPC-157” may refer to different API forms. FDA distinguishes BPC-157 free base from BPC-157 acetate and has identified concerns involving identity, characterization, aggregation and peptiderelated impurities.

Possible side effects

Observed Human Study Adverse Events

In the rectal healthy-volunteer work, the most commonly reported events were:

• headache

• flatulence

with no obvious difference from placebo in the available meeting abstracts.

The small knee, bladder and IV studies reported no major adverse events in their limited cohorts.

Evidence limitation Those cohorts are far too small to determine:

• true incidence

• rare adverse events

• chronic toxicity

• reproductive safety

• carcinogenic risk

Community-Reported Side Effects

Community reports include:

• fatigue

• nausea

• dizziness

• headache

• injection discomfort

• flushing

• appetite changes

• sleep changes

• subjective mood changes

Classification Community-reported / causality uncertain Do not assign precise incidence percentages or confident mechanisms.

Animal Toxicology Signals

FDA’s 2026 review identified potentially relevant repeat-dose animal findings.

In 28-day IM studies, reported signals included:

• shortened aPTT in rats

• prolonged aPTT in dogs

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 23

• increased ALT

• increased glucose

• increased triglycerides

FDA noted that longer-duration repeat-dose studies were unavailable to determine whether these findings persist or whether additional signals emerge.

Correct classification Animal toxicology signals not:

Established human adverse effects But these findings make it inappropriate to describe long-term systemic safety as fully established.

Immunogenicity / Aggregation

This is one of FDA’s central concerns.

FDA found problems involving:

• inconsistent chemical naming

• incomplete impurity characterization

• potential peptide aggregation

• incomplete microbial information

• incomplete endotoxin information

• potential immunogenicity, especially for injectable formulations

FDA’s current safety-risk page likewise says BPC-157 may present immunogenicity concerns for certain routes and that peptide-related impurities and API characterization are important uncertainties.

Why this matters Injectable risk is not determined only by:

dose It can also depend on:

• API identity

• free base versus acetate

• peptide purity

• synthesis byproducts

• aggregation

• endotoxin

• microbial contamination

• formulation

• storage

• concentration accuracy

Cancer / Angiogenesis

BPC-157 has experimental pro-angiogenic activity.

VEGFR2-related signaling has been implicated in laboratory and animal research.

That creates a biologically reasonable concern in conditions involving abnormal vascular growth.

However:

EDUCATIONAL RESEARCH SUMMARY | BPC-157 | AUDITED EVIDENCE STANDARD Page 24

No human clinical cancer-risk dataset establishes that BPC-157 causes tumor growth.

FDA also found no adequate carcinogenicity studies for BPC-157 free base or acetate.

Correct classification Unresolved theoretical / mechanism-based safety concern Do not write:

“BPC-157 causes cancer .”

Also do not write:

“BPC-157 is proven cancer-safe.”

Neither claim is established.

Compatibility

Same-Vial / Same-Syringe Compatibility

A common assumption is:

“These peptides are used together , therefore they are chemically compatible together .”

That does not follow.

For BPC-157 combinations, Navaro should not assume validated:

• physical compatibility

• chemical compatibility

• pH compatibility

• solubility

• potency retention

• aggregation behavior

• degradation rate

• beyond-use period

unless the exact formulation has been tested.

Production verdict Community co-use ≠ validated same-vial compatibility

Sources

Navaro Compounds 2.pdf, pages 39–79.